Company profile: Canbex Therapeutics
1.1 - Company Overview
Company description
- Provider of treatments for spasticity in multiple sclerosis (MS) and other disorders, targeting the debilitating symptom of involuntary spasms and stiffness of limbs and torso, with a lead programme focused on improving the lives of people with this serious and incurable disorder.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Canbex Therapeutics
Magstim
HQ: United Kingdom
Website
- Description: Provider of Transcranial Magnetic Stimulation (TMS) stimulators and packages for Magstim TMS therapy and neuromodulation research. Offers Magstim TMS Therapy for depression, StimGuide for precise TMS delivery, and Neurosign intraoperative nerve monitoring solutions. Provides installation, certification training, and dedicated engineering service and support. Magstim stimulators are used in the majority of published TMS research.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Magstim company profile →
Pherin
HQ: United States
Website
- Description: Provider of clinical-stage investigational drugs for psychiatric and neurological disorders, particularly anxiety and depression, developing pherines (a new class of drugs) and an oral antagonist targeting the glycine site of the N-methyl-D-aspartate receptor (NMDAR). Privately held.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pherin company profile →
Neuraxpharm
HQ: Germany
Website
- Description: Provider of branded and generic CNS pharmaceuticals and nutraceuticals in main European countries, developing and commercializing products for CNS disorder prevention and treatment. Develops and manufactures finished dosage forms (mainly solid oral) for CNS and other areas; includes Buccolam for acute pediatric seizures and Preventan for immune support. Also offers LepsiApp for epilepsy management, R&D (actives, bioequivalence, regulatory), and pharmacovigilance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neuraxpharm company profile →
Cavion
HQ: United States
Website
- Description: Provider of clinical-stage therapies targeting T-type calcium channels (Cav3) for cancer and neurologic diseases, including CX-8998, a modulator in Phase 2 for essential tremor and absence epilepsy, and Mibefradil, a partially selective blocker tested with hypofractionated radiation in recurrent glioblastoma multiforme.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cavion company profile →
Astex Pharmaceuticals
HQ: United Kingdom
Website
- Description: Provider of novel small-molecule therapeutics discovery and development using its pioneering fragment-based drug discovery platform, Pyramid™. The UK-based company has built a pipeline of molecularly-targeted oncology drugs, with three in clinical trials and others in discovery and pre-clinical stages.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Astex Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Canbex Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Canbex Therapeutics
2.2 - Growth funds investing in similar companies to Canbex Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Canbex Therapeutics
4.2 - Public trading comparable groups for Canbex Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →